Resource Logo

Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: a pilot study.


New Microbiol. 1996 Oct;19(4):351-5. Unique Identifier : AIDSLINE

Oral candidiasis frequently occurs in HIV-positive patients especially in those with advanced disease. To date, common anti-mycotic drugs are unable to prevent relapses and alternative therapy is necessary to reduce disabling effects. With the aim of verifying whether thymic hormone extract may be efficacious in these subjects, we enrolled 10 HIV-positive patients with recurrent and/or persistent oral candidiasis to be treated with thymopentin (oral inhalations). All patients benefited from the topical use of thymopentin, and in all cases there was marked increase in salivary secretory IgA which possibly accounted for the candidiasis improvement.

*Adjuvants, Immunologic/THERAPEUTIC USE *AIDS-Related Opportunistic Infections/DRUG THERAPY *Candidiasis, Oral/DRUG THERAPY *IgA, Secretory/ANALYSIS *Thymopentin/THERAPEUTIC USE


Information in this article was accurate in July 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.